ArticleMovement disorders clinical practice2026
Motor and Cognitive Outcome After Subthalamic Nucleus Deep Brain Stimulation in Patients with Parkinson's Disease Harboring GBA1 Variant.
Article in Movement disorders clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Nonmotor Symptoms in Parkinson's Disease: Neurophysiology Biomarkers and Neuromodulation Approaches.Stereotactic and functional neurosurgery · 2026Review
- Midbrain length by the one-line method predicts motor outcome after deep brain stimulation in Parkinson's disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Long-Term Mortality and 10-Year Outcomes after Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease.Stereotactic and functional neurosurgery · 2026Article
- Clinical Utility ofGenes · 2026Review
- Improved oxygen saturation after deep brain stimulation in Parkinson's disease.Neurosurgical review · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDeep brain stimulation (DBS) is effective for Parkinson's disease (PD); however, its efficacy varies with genetic background, such as the GBA1 variant-the causative gene of Gaucher disease-associated with increased PD risk and cognitive decline after subthalamic nucleus (STN)-DBS.
objectivesThe aim of the study was to examine the relationship between outcomes after STN-DBS and GBA1 variants in PD patients undergoing bilateral STN-DBS.
methodsPatients were retrospectively analyzed over 5 years, with clinical and genetic assessments, including GBA1 variant status performed at baseline and at 1-, 3-, and 5-years post-DBS. Longitudinal changes in motor, cognitive, and medication outcomes were evaluated using propensity score matching and linear mixed-effects models.
resultsA total of 371 PD patients undergoing bilateral STN-DBS were analyzed, including 54 GBA1 variant carriers and 253 noncarriers, after excluding other genetic variants. Propensity score matching yielded 2 groups with balanced baseline characteristics, with 50 patients each. Over time, no significant differences were observed in motor, cognitive, or neuropsychiatric assessments between groups. GBA1 carriers exhibited worsened medication OFF-DBS off state motor symptoms at 5 years postoperatively, whereas cognitive function, assessed by the Mini-Mental State Examination, remained stable in both groups. Levodopa-equivalent daily dose (LEDD) significantly decreased in both groups. Linear mixed-effects models showed progressive motor and cognitive decline and reduced medication use over 5 years, with no significant impact on GBA1 variant status.
conclusionsFindings from Japan's largest genetic cohort suggest that GBA1 variants may not significantly affect postoperative motor or cognitive trajectories following STN-DBS. Further validation through large-scale multinational and multicenter studies is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.